Epithalon (Injectable Form)

Pending PCAC

Also known as: Epitalon Injectable, AEDG Injectable, Ala-Glu-Asp-Gly SC

Anti-Aging & Longevity

Last reviewed: April 28, 2026

The injectable subcutaneous form of the Epithalon tetrapeptide, offering higher bioavailability than oral or nasal routes. Same active sequence (Ala-Glu-Asp-Gly) as oral Epitalon but delivered via injection for more reliable absorption. Studied for telomerase activation, pineal gland function, and circadian rhythm regulation.

Mechanism of Action

Same mechanism as oral Epitalon — stimulates telomerase activity in somatic cells, potentially slowing telomere shortening. Also modulates pineal gland melatonin production and may influence circadian rhythm regulation. The injectable route bypasses GI degradation, providing more consistent peptide delivery to target tissues.

Common Uses

  • Anti-aging and longevity protocols
  • Telomere maintenance (investigational)
  • Sleep quality improvement
  • Circadian rhythm regulation
  • Pineal gland support

Known Risks

  • Injection site reactions
  • Drowsiness (melatonin-related)
  • Limited human clinical data
  • Long-term safety unknown
  • Theoretical cancer risk from telomerase activation (unproven)

Regulatory Status

Pending PCAC

Shares regulatory status with Epitalon. Removed from Category 2 on April 22, 2026. Scheduled for PCAC Day 2 review on July 24, 2026. Not FDA-approved for any indication.

PCAC Review Scheduled:2026-07-24View full timeline →

Get notified when the PCAC decides on Epithalon (Injectable Form)

Scheduled review: 2026-07-24. We'll email you the same day results are announced.

Common Protocols

Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.

Subcutaneous injection

Typical Dose

5–10 mg per injection

Frequency

Once daily for 10–20 days

Cycle Length

10–20 day course, repeated every 4–6 months

The Khavinson protocol uses 10 mg daily for 10 days, repeated every 6 months. Inject subcutaneously in the abdominal area. Reconstitute with bacteriostatic water. Some practitioners combine with Pinealon for synergistic pineal gland support. Evening administration may enhance melatonin-related effects.

Related Compounds

Research References

This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.